Subgroup analyzes

Related by string. subgroup analyzes * Subgroups . subgroups . subgroup : economically disadvantaged subgroup . economically disadvantaged subgroups . demographic subgroups . discrete subgroups . Bayer HealthCare subgroup . subgroups Bayer HealthCare / ANALYZE . Analyzes . Analyze : analyze nucleic acids . Find Compare Analyze . meta analyzes . statistical analyzes . collects analyzes * *

Related by context. Frequent words. (Click for all words.) 74 subgroup analyzes 71 multivariate analyzes 68 univariate 66 genetic polymorphisms 66 lipid lowering drugs 66 biochemical recurrence 66 lipid lowering therapy 65 elevated CRP 65 RCTs 65 neuropsychiatric symptoms 65 prognostic factors 64 univariate analysis 64 liver transplant recipients 64 serum PSA 64 MetS 64 lymph node involvement 63 Epidemiological studies 63 virologic failure 63 FDG PET 63 thromboembolism 63 HbA 1c 63 androgen deprivation 63 generalizability 63 neoadjuvant therapy 63 placebo controlled trials 63 myocardial ischemia 63 substudy 63 immunohistochemical 63 thromboembolic events 63 T2DM 63 RRMS patients 63 covariates 62 microalbuminuria 62 Secondary endpoints 62 histologic 62 LUTS 62 multivariate analysis 62 hsCRP 62 fasting insulin 62 histopathological 62 comorbid conditions 62 antihypertensive drugs 62 vertebral fracture 62 randomized trials 62 lymph node metastases 62 comorbidities 62 comorbidity 62 contralateral breast cancer 61 PREZISTA r 61 neoadjuvant 61 virologic response 61 PCa 61 KRAS mutations 61 nonsignificant 61 achieved statistical significance 61 retrospective cohort study 61 hepatotoxicity 61 rheumatoid factor 61 cystatin C 61 HSCT 61 coronary artery calcification 61 mycophenolate mofetil 61 oophorectomy 61 seroprotection 61 colorectal adenomas 61 preoperative 61 renal toxicity 61 nonadherence 61 serum uric acid 61 coronary angiography 61 chemoradiotherapy 60 cerebrovascular events 60 serum concentrations 60 P = .# 60 fasting glucose levels 60 adjuvant chemotherapy 60 glomerular filtration rate 60 potential confounders 60 EGFR mutations 60 atherothrombosis 60 tocilizumab 60 ALLHAT 60 perinatal mortality 60 echocardiographic 60 reperfusion therapy 60 adjuvant therapy 60 ischemic cardiomyopathy 60 coronary revascularization 60 subclinical 60 tamsulosin 60 nonresponders 60 serologic 60 knee OA 60 renal dysfunction 60 estimated glomerular filtration 60 distant metastases 60 anticholinergics 60 placebo controlled clinical trials 60 Pharmacokinetic 60 statistically significant p = 60 proportional hazards

Back to home page